TRVI

Trevi Therapeutics (TRVI) Q4 Loss Narrows to $0.06/Share vs $0.10 Estimate, 37% Better Than Expected

6 hours ago

Trevi Therapeutics narrows Q4 loss to $0.06 per share, beating estimates by 37% as the pre-revenue biotech maintains unanimous analyst…

4 years ago

Trevi Therapeutics, Inc (NASDAQ: TRVI) Q4 2021 Earnings Conference

4 years ago

Trevi Therapeutics, inc (NASDAQ: TRVI) Q3 2021 Earnings Conference

5 years ago

Trevi Therapeutics, inc (NASDAQ: TRVI) Q2 2021 Earnings Conference

5 years ago

Trevi Therapeutics, inc (NASDAQ: TRVI) Q4 2020 Earnings Conference